


Supplementary Materials

I. PRISMA 2009 Flow Diagram:



II. PICOS-T

Component	Description
Population (P)	Adult patients with metastatic triple-negative breast cancer (mTNBC) treated in real-world settings
Intervention (I)	Sacituzumab govitecan (SG)
Comparator (C)	Not applicable / none
Outcomes (O)	Efficacy outcomes including overall response rate (ORR), complete response rate (CRR), overall survival (OS), and progression-free survival (PFS)
Study Design (S)	Observational real-world studies
Time Period (T)	Studies published up to December 2025

III. Bibliography

- [1] Martorana F, Sanò MV, Fabi A, Paris I, Leonardi V, Bini G, et al. A multicenter real-life evaluation of safety and effectiveness of the antibody-drug conjugate sacituzumab govitecan in metastatic triple-negative breast cancer. *Am J Clin Oncol*. 2025 May 19. doi:10.1097/COC.0000000000001201.
- [2] Muğlu H, Helvacı K, Köylü B, Yücel MH, Celayir ÖM, Demirci U, et al. The clinical outcomes and safety of sacituzumab govitecan in heavily pretreated metastatic triple-negative and HR+/HER2– breast cancer: a multicenter observational study from Turkey. *Cancers (Basel)*. 2025;17(9):1592. doi:10.3390/cancers17091592.
- [3] Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, et al. Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer. *JCO Oncol Pract*. 2025 May;21(5):620–628. doi:10.1200/OP.24.00242.
- [4] Püsküllüoğlu M, Pieniżek M, Las-Jankowska M, Streb J, Ziobro M, Pacholczak-Madej R, et al. Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a Polish real-world multicenter cohort study. *Oncol Ther*. 2024 Dec;12(4):787–801. doi:10.1007/s40487-024-00307-1.
- [5] Carrión-Madroñal IM, Díaz-Acedo R, Lora-Escobar SJ, Naranjo-Llamas E, Jaramillo-Ruiz D, Artacho-Criado S, et al. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study. *Future Oncol*. 2024;20(33):2565–2572. doi:10.1080/14796694.2024.2394408.
- [6] Schäffler H, Jakob D, Huesmann S, Pfister K, Veselinovic K, Schochter F, et al. Novel antibody-drug conjugates in routine clinical practice for the treatment of metastatic breast cancer: adherence, efficacy and tolerability—real-world data from German breast centers. *Geburtshilfe Frauenheilkd*. 2024 Sep;84(9):855–865. doi:10.1055/a-2375-5194.
- [7] Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, et al. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. *Breast Cancer Res Treat*. 2024 Nov;208(1):203–214. doi:10.1007/s10549-024-07412-9.
- [8] Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, et al. Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. *Br J Cancer*. 2024 Jun;130(12):1916–1920. doi:10.1038/s41416-024-02685-9.

- [9] De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie hospitals: efficacy, safety, and impact of brain metastases. *Breast Cancer*. 2024 Jul;31(4):572–580. doi:10.1007/s12282-024-01565-7.
- [10] Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, et al. Sacituzumab govitecan for the treatment of advanced triple-negative breast cancer patients: a multi-center real-world analysis. *Front Oncol*. 2024 Mar 26;14:1362641. doi:10.3389/fonc.2024.1362641.
- [11] Reinisch M, Bruzas S, Spoenlein J, Shenoy S, Traut A, Harrach H, et al. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. *Ther Adv Med Oncol*. 2023 Sep 28;15:17588359231200454. doi:10.1177/17588359231200454.
- [12] Pieniżek M, Polakiewicz-Gilowska A, Las-Jankowska M, Wronowicz J, Jarzab M, Łacko A, et al. Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis. *Breast Cancer Res Treat*. 2025 Dec;214(3):397–407. doi:10.1007/s10549-025-07825-0.
- [13] Tunbekici S, Sahin G, Ön S, Oruc A, Eryilmaz MK, Sakin A, et al. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: a multicenter study by the Turkish Oncology Group. *Int J Cancer*. 2025 Oct 28. doi:10.1002/ijc.70213.
- [14] Morganti S, Kusmick RJ, Hughes ME, Brasó-Maristany F, Smith K, Tarantino P, et al. Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer. *ESMO Open*. 2025 Oct;10(10):105828. doi:10.1016/j.esmoop.2025.105828.
- [15] Lago-Ballester F, Martínez-Orea A, Laorden-Carrasco A, Díaz-Carrasco MS, Titos-Arcos JC, Mira-Sirvent MC, et al. Effectiveness and safety of sacituzumab govitecan in real-world clinical practice in patients with metastatic triple-negative and HR+/HER2-negative breast cancer. *Biomedicines*. 2025;13(9):2059. doi:10.3390/biomedicines13092059.
- [16] Pieniżek M, Polakiewicz-Gilowska A, Las-Jankowska M, Wronowicz J, Jarzab M, Łacko A, et al. Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for metastatic triple-negative breast cancer in the Polish female cohort. *Ther Adv Med Oncol*. 2025 Aug 19;17:17588359251363104. doi:10.1177/17588359251363104.
- [17] Nanda R, Yam C, Spring L, Bhave MA, Ntalla I, Valdez T, et al. Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. *ESMO Open*. 2025 Jun;10(6):105308. doi:10.1016/j.esmoop.2025.105308.